FDA

After a year of investigation the US Food and Drug Administration (FDA) has completely withdrawn all ranitidine products from the American market. Studies have revealed levels of a carcinogenic compound can increase in the product over time, particularly when stored at high temperatures.

“Use it or lose it” applies to muscles, but unfortunately so does “don’t use it too much or lose it.” Now, researchers at Temple University have tested a drug that appears to reverse muscle damage from overuse injuries in rats.

After a decade of legal and political battles, the FDA finally issued a conclusive new ruling for warnings on cigarette packs. The 11 new labels will fill 50 percent of the package with text and graphic imagery depicting the consequences of smoking.

Colloidal silver, herbal supplements and essential oils are among a number of products currently being fraudulently promoted as cures for COVID-19, as the US Food and Drug Administration targets seven companies peddling unproven treatments.

Research from a team of US scientists is again raising doubt over the safety of “BPA-free” plastic products. The animal studies described in a new article suggest bisphenol S (BPS) “causes almost identical changes in gene expression” compared to BPA.

Research has confirmed chemicals in sunscreen can be detected in the blood of users after just one application. But experts urge people continue using sunscreen as there is no evidence to suggest these findings point to negative health consequences.

Marking an impressive milestone in the development of MDMA-assisted psychotherapy for PTSD, the FDA has approved the treatment for Expanded Access, allowing certain patients access to the therapy before full market approval is granted.

A Phase 3 clinical trial into the efficacy of a fish-oil-derived drug called Epanova has been discontinued. The trial was designed to establish the use of the drug, a formulation of two omega-3 fatty acids, as an adjunct to statins for heart disease.

A promising new cancer drug will soon enter phase 2 clinical trials, after finding success in animal models and preliminary human studies. Known as AMG 510, the drug targets a gene mutation that’s one of the most common causes of cancer.

Continuing the wave of cutting-edge new migraine drugs reaching the American market, the U.S. Food and Drug Administration (FDA) has now approved the first oral calcitonin gene-related peptide (CGRP) antagonist for acute migraine treatment.

After months of concern, the CDC has revealed it's confident in claiming the “vast majority” of recent lung injury cases related to e-cigarette use can be linked to illicit THC vape liquids containing vitamin E acetate.

The FDA has finally approved two new low-nicotine cigarettes for the US market. The announcement comes less than a month after the FDA faced criticism for seemingly backing down on a 2017 initiative to regulate nicotine levels in cigarettes.